Across Tennessee and the broader United States, a new and especially dangerous drug trend has taken hold. You may hear it called “tranq,” “tranq dope,” or just assume it is fentanyl. But what is actually showing up in more and more overdose cases is xylazine, a veterinary sedative that was never meant for human use.
Understanding what xylazine is, how it works, and why it is showing up in the drug supply is critical. It is changing the risks of opioid use in ways that many people do not fully realize.
What Is Xylazine?
Xylazine is a veterinary medication used to sedate large animals like horses and cattle. It is not approved for human use.
It works as a central nervous system depressant, meaning it slows down brain activity, breathing, and heart rate. On its own, it can cause heavy sedation. But it becomes especially dangerous when mixed with opioids like fentanyl.
“Tranq” is street slang for drugs that have been mixed with xylazine.
Most often, this means fentanyl has been cut with xylazine to extend or alter the high. The combination creates a longer-lasting sedative effect, but it also introduces serious and unpredictable risks.
Many people do not know they are using xylazine at all. It is not something you can see, smell, or reliably detect without testing.
Why Xylazine Is So Dangerous
1. It Does Not Respond to Naloxone
One of the biggest risks with xylazine is that it is not an opioid.
That means medications like Naloxone (Narcan) do not reverse its effects.
Naloxone can still save someone if opioids are involved, which they usually are. But it will not reverse the sedative effects of xylazine itself. This can leave someone sedated or not breathing even after Narcan is given.
2. It Deepens Breathing Suppression
When combined with fentanyl or other opioids, xylazine increases the risk of respiratory depression.
In simple terms, it makes it more likely that breathing will slow down or stop entirely.
3. It Causes Severe Skin Wounds
One of the most visible and alarming effects of xylazine is the development of serious skin wounds.
These can happen even in people who do not inject drugs. The wounds may start small but can quickly become deep, infected, and difficult to treat. In severe cases, they can lead to tissue death and even amputation.
4. It Increases Overdose Risk in Unpredictable Ways
Because xylazine is not consistently measured or disclosed in the drug supply, people have no way of knowing how much they are using.
This unpredictability increases overdose risk significantly.
Signs of Xylazine Exposure
Symptoms can look similar to an opioid overdose, but with some differences:
- Extreme drowsiness or unresponsiveness
- Slow or stopped breathing
- Low heart rate
- Low blood pressure
- Skin ulcers or unusual wounds
- Prolonged sedation even after Narcan is given
If someone is unresponsive or not breathing, it is always an emergency.
What To Do in an Overdose Situation
Even though xylazine does not respond to naloxone, you should still use it.
- Call 911 immediately
- Administer naloxone if available
- Try to keep the person breathing
- Stay with them until help arrives
Naloxone can still reverse the opioid portion of the overdose, which can be life-saving.
Why Xylazine Is Showing Up More Often
Drug manufacturers and distributors often add substances like xylazine to stretch supply and increase perceived potency.
It is cheaper than fentanyl and can make the effects last longer. But it also makes the drug supply far more dangerous and unpredictable.
What Makes Tranq (Xylazine) Different From Other Drugs in the Supply?
Most people think the danger comes from fentanyl alone. That is no longer the full picture.
Xylazine introduces a second mechanism of harm that is not opioid-based. It acts on alpha-2 adrenergic receptors, which suppress the central nervous system in a different way than opioids. This means you are dealing with stacked sedation from two separate systems, which is why overdoses are harder to reverse and often last longer.
Another major difference is that xylazine creates physiological dependence that does not respond to traditional opioid withdrawal protocols alone. People may stabilize from opioid withdrawal but still feel intense symptoms from xylazine itself.
The Hidden Risk: Why People Don’t Realize They’re Using It
Xylazine is rarely sold on its own. It is almost always mixed into fentanyl or heroin.
That creates three major problems:
- There is no consistent dosing, even within the same batch
- Standard drug tests often do not screen for xylazine
- People assume Narcan will fully reverse an overdose, which is not always true
This disconnect is one of the biggest reasons overdose deaths involving xylazine have risen so quickly.
Xylazine Withdrawal Is Often Misunderstood
Unlike opioids, xylazine withdrawal can include symptoms that feel more like a mix of opioid withdrawal and severe anxiety or autonomic instability.
Clinically, this can look like:
- Intense agitation and restlessness
- Rapid heart rate and elevated blood pressure rebound
- Severe anxiety or panic
- Insomnia that lasts longer than typical opioid withdrawal
- Ongoing cravings even after opioid stabilization
This is why detox needs to be medically managed. Treating only the opioid side is often not enough.
Why Wounds Develop (And Why They’re So Severe)
The wounds associated with xylazine are not just from injection.
Xylazine appears to cause vasoconstriction, which reduces blood flow to tissues. Over time, this can lead to:
- Tissue breakdown
- Poor healing
- High infection risk
This explains why wounds can show up in areas that were never injected and why they can progress quickly.
At-a-Glance Comparison: Xylazine vs. Fentanyl vs. Heroin
| Feature | Xylazine (Tranq) | Fentanyl | Heroin |
|---|---|---|---|
| Drug Type | Veterinary sedative (non-opioid) | Synthetic opioid | Semi-synthetic opioid |
| Approved for Human Use | No | Yes (medical settings) | No |
| Responds to Naloxone | No | Yes | Yes |
| Primary Effect | Heavy sedation, CNS depression | Pain relief, euphoria, respiratory depression | Euphoria, pain relief |
| Overdose Risk | High, especially when mixed | Extremely high | High |
| Breathing Suppression | Yes | Yes (primary cause of death) | Yes |
| Causes Skin Wounds | Yes, severe and unique | Not typical | Not typical |
| Detectable on Standard Drug Screens | Often no | Yes | Yes |
| Withdrawal Profile | Complex, non-opioid + opioid overlap | Opioid withdrawal | Opioid withdrawal |
| Duration of Sedation | Prolonged, unpredictable | Short but intense | Moderate |
What This Means for Real-World Risk
This is the part most blogs miss.
With fentanyl alone, there is at least a known emergency response pathway. Naloxone works, even if multiple doses are needed.
With xylazine involved, you now have situations where:
- Someone receives Narcan and still does not wake up
- Breathing remains suppressed even after opioid reversal
- First responders have to rely on airway support and time, not just medication
That changes how dangerous each use becomes. It also means people may falsely assume Narcan “didn’t work,” when in reality it reversed the opioid but not the xylazine.
Clinical Takeaway
From a treatment perspective, tranq changes the approach in three key ways:
- Detox may take longer and require more monitoring
- Wound care becomes part of addiction treatment
- Relapse risk is higher due to dual withdrawal patterns
This is why a structured setting like Brooks Healing Center can make a real difference. It allows both the medical and behavioral sides to be addressed at the same time, instead of trying to manage a more complex withdrawal alone.
Treatment for Tranq and Xylazine Use
There is no FDA-approved medication specifically for xylazine withdrawal. That makes treatment more complex. However, recovery is still possible with the right level of care.
At a licensed treatment center like Brooks Healing Center, care may include:
- Medical detox with monitoring for complications
- Treatment for opioid use disorder, often including medications
- Wound care and infection management
- Individual and group therapy
- Long-term relapse prevention planning
Because xylazine is often combined with opioids, treating both the physical and psychological aspects of addiction is essential.
Why Early Treatment Matters
Xylazine changes the risks of substance use in a real and immediate way. People are not just dealing with addiction anymore. They are dealing with a drug supply that is more toxic, less predictable, and harder to reverse in an emergency.
Getting help early can reduce the risk of overdose, serious medical complications, and long-term damage.
A Simple Way to Think About It
Fentanyl alone is already extremely dangerous. Adding xylazine makes it more unpredictable, harder to reverse, and more physically damaging.
That combination is why “tranq” has become such a serious concern.
If You or Someone You Love Needs Help
If you are noticing signs of opioid use, unusual wounds, or increased sedation, it may be time to seek support.
Reaching out does not lock you into anything. It just opens the door to understanding what is going on and what your options are.
At Brooks Healing Center, the goal is simple. Meet people where they are and help them move forward safely.
Frequently Asked Questions About Xylazine
What is tranq?
“Tranq” is a street term used to describe drugs that have been mixed with xylazine, a veterinary sedative. It is most often found in fentanyl or heroin. Many people do not realize they are using xylazine because it is added without their knowledge. The combination creates a longer-lasting sedative effect but also increases the risk of overdose and serious medical complications.
What is the “zombie drug”?
The term “zombie drug” is a media nickname for xylazine or tranq. It comes from the way the drug can cause extreme sedation, slowed movement, and visible physical decline, including severe skin wounds. While the term gets attention, it can be misleading and stigmatizing. The reality is that xylazine is a powerful sedative affecting the nervous system, not something that turns people into “zombies.”
Why do humans take xylazine?
Most people are not intentionally seeking out xylazine. It is usually consumed unknowingly when mixed into other drugs like fentanyl. In some cases, people may seek it out because it can extend the duration of a high or create a deeper sedative effect. However, this comes with significantly higher risks, including overdose that is harder to reverse and more severe physical complications.
Is xylazine a controlled substance?
Xylazine is not classified as a controlled substance at the federal level in the United States. It is regulated as a veterinary drug, not a human medication. However, due to its increasing role in overdose deaths, some states have begun placing restrictions or reclassifying it. Laws are evolving quickly, so its legal status can vary depending on location.
Is xylazine ketamine?
No, xylazine is not ketamine.
While both are used in veterinary medicine as sedatives, they work very differently. Ketamine is a dissociative anesthetic that is also used in human medicine under supervision. Xylazine is an alpha-2 adrenergic agonist that depresses the central nervous system and is not approved for human use. Confusing the two can be dangerous because their effects, risks, and treatment approaches are not the same.
Why does xylazine cause skin ulcers?
Xylazine appears to reduce blood flow to tissues by causing vasoconstriction, which means the blood vessels tighten. Over time, this can damage the skin and underlying tissue, leading to ulcers that are slow to heal. These wounds can develop even in areas where the drug was not injected and may worsen quickly without proper medical care.
What does xylazine look like?
Xylazine in its medical form is typically a clear liquid used for veterinary injection. In the illicit drug supply, it does not have a consistent appearance because it is mixed into other substances.
When combined with fentanyl or heroin, it may appear as a powder that is:
– White
– Off-white
– Tan
– Light brown
There is no reliable way to identify xylazine by sight alone. This is part of what makes it so dangerous, since people often cannot tell whether it is present in a substance they are using.
Sources
- Centers for Disease Control and Prevention. (2024, May 16). What you should know about xylazine. Retrieved from https://www.cdc.gov/overdose-prevention/about/what-you-should-know-about-xylazine.html
- Centers for Disease Control and Prevention. (2024). Xylazine: Clinical management and harm reduction strategies for patients (PDF). Retrieved from https://www.cdc.gov/overdose-prevention/media/pdfs/2024/07/Xylazine-Clinical-Management-and-Harm-Reduction.pdf
- U.S. Food and Drug Administration. (2022, November 8). FDA alerts health care professionals of risks to patients exposed to xylazine in illicit drugs. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals-risks-patients-exposed-xylazine-illicit-drugs
- Drug Enforcement Administration. (n.d.). Xylazine information. Retrieved from https://www.dea.gov/xylazine-information
- National Institute on Drug Abuse. (n.d.). Xylazine. Retrieved from https://nida.nih.gov/research-topics/xylazine
- D’Orazio, J., Nelson, L., Perrone, J., Wightman, R., & Haroz, R. (2023). Xylazine adulteration of the heroin-fentanyl drug supply: A narrative review. Annals of Internal Medicine, 176(10), 1370–1376. Retrieved from https://pubmed.ncbi.nlm.nih.gov/37812779/
- Gupta, R., Shah, N. D., & Ross, J. S. (2023). Xylazine: Medical and public health imperatives. The New England Journal of Medicine, 388(24), 2209–2212. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMp2303120
- Tennessee Department of Health. (2024, March 19). Emerging trends: Xylazine (PDF). Retrieved from https://www.tn.gov/content/dam/tn/health/documents/pdo/emerging-trend-archive/Emerging_Trends_Xylazine_3.19.24.pdf
- Tennessee Department of Mental Health and Substance Abuse Services. (2023). Emerging substances: Xylazine. Retrieved from https://www.tn.gov/behavioral-health/substance-abuse-services/prevention/emerging-substances.html
- Kentucky Cabinet for Health and Family Services, Department for Public Health. (2023). Emerging threat: Xylazine (PDF). Retrieved from https://www.chfs.ky.gov/agencies/dph/Harm%20Reduction/Emerging%20Threat%20Xylazine%20Infographic.pdf
- Kentucky Office of Drug Control Policy. (2025). 2024 Kentucky overdose fatality report (PDF). Retrieved from https://odcp.ky.gov/Reports/2024%20Drug%20Overdose%20Fatality%20Report.pdf
